Drug class
C-X-C chemokine receptor 4 (CXCR4) antagonist; haematopoietic stem-cell mobiliser
Mechanism of action
Blocks CXCR4 binding to its ligand CXCL12/SDF-1α, disrupting retention and homing of haematopoietic stem cells in the bone marrow and mobilising CD34-positive stem cells into peripheral blood.
General use cases
- In combination with filgrastim (G-CSF) to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma; not indicated for stem-cell mobilisation in leukaemia
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
